Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NO and angiogenesis.

John P Cooke1

  • 1Program in Vascular Medicine and Biology, Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305-5406, USA. john.cook.e@stanford.edu

Atherosclerosis. Supplements
|December 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human BMP4 mRNA Encapsulated in Lipid Nanoparticle for Bone and Articular Cartilage Repair in Aged Mice.

Journal of functional biomaterials·2026
Same author

Investigational New Drug-enabling studies in a human vessel-chip: Are we there yet?

Bioengineering & translational medicine·2026
Same author

Telomerase is induced during wound healing across species.

Skin health and disease·2026
Same author

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis.

Circulation research·2026
Same author

A Long-lived Avatar for Modeling Age-Related Vascular Disease.

bioRxiv : the preprint server for biology·2026
Same author

Shear cytokine crosstalk is a determinant of SARS-CoV-2-induced endothelial pathophysiology and thrombosis in human vessel chips.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members.

Atherosclerosis. Supplements·2021
Same journal

Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.

Atherosclerosis. Supplements·2021
Same journal

Lipid Clinics Network. Rationale and design of the EAS global project.

Atherosclerosis. Supplements·2021
Same journal

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.

Atherosclerosis. Supplements·2021
Same journal

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same journal

Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atherosclerosis. Supplements·2021
See all related articles

Nitric oxide (NO) is crucial for blood vessel formation (angiogenesis). Inhibiting NO, like with asymmetric dimethylarginine (ADMA), hinders angiogenesis, while boosting NO enhances it, offering therapeutic potential.

Area of Science:

  • Biomedical science
  • Vascular biology
  • Molecular medicine

Background:

  • Angiogenesis, the formation of new blood vessels, is a critical physiological process.
  • Endothelium-derived nitric oxide (NO) plays a vital role in regulating angiogenesis.
  • Dysregulation of NO synthesis is implicated in various vascular pathologies.

Purpose of the Study:

  • To elucidate the role of nitric oxide (NO) in angiogenesis.
  • To investigate the impact of NO synthase (NOS) pathway modulation on angiogenic processes.
  • To explore the therapeutic potential of targeting the NO pathway for angiogenesis-related disorders.

Main Methods:

  • Review of literature on NO synthesis and its role in endothelial cell functions.
  • Analysis of studies investigating the effects of NOS inhibitors (e.g., ADMA) and enhancers (e.g., statins) on angiogenesis.

Related Experiment Videos

  • Examination of NO-modulated cellular processes including survival, proliferation, and migration.

    • Main Results:

    • Angiogenic factors stimulate endothelial cells to release NO, which is essential for angiogenesis.
    • NO modulates key angiogenic processes: endothelial cell survival, proliferation, migration, and extracellular matrix interaction.
    • Inhibition of the NOS pathway, exemplified by asymmetric dimethylarginine (ADMA), impairs angiogenesis.
    • Agents that increase NO synthesis, such as low-dose statins, promote angiogenesis.

    Conclusions:

    • The nitric oxide (NO) synthase pathway is a critical regulator of angiogenesis.
    • Modulating NO bioavailability presents a promising therapeutic strategy for angiogenesis-related conditions.
    • Targeting the NO pathway offers a novel avenue for treating vascular disorders characterized by impaired or excessive angiogenesis.